SunTrust analyst Peter Lawson raised his price target on Mirati Therapeutics to $60 and kept his Buy rating. The analyst cites the findings from his recent investor meetings with the management highlighting the "solid positioning and differentiated approach with sitra in immuno-oncology combination" as well as a solid set of catalysts expected in the second half. Lawson adds that he is increasingly confident about Mirati in IO relapsed and refractory non-small cell lung cancer, raising his estimated penetration rate to 30% from 20% while also boosting the likelihood of approval to 40% from 33%.